logo-loader
viewAkers Biosciences, Inc.

Proactive Innovation Forum this week: Rex Bionics, Akers, accesso and Alliance Pharma

The excitement is building ahead of the Proactive Investors’ Innovation Forum later this week that will showcase the next generation of big hitters in the technology.

speech_350_5534ec1166b9a.jpg

The excitement is building ahead of the Proactive Investors’ Innovation Forum later this week that will showcase the next generation of big hitters in the technology.

We are pleased to present Rex Bionics (LON:RXB), Accesso Technology group (LON:ACSO), Akers Biosciences (LON:AKR) and Alliance Pharma (LON:APH).

And as you’ll see the event, being held at The Chesterfield Hotel, 35 Charles Street, Mayfair, this Thursday from 6pm, has something for almost every investor’s palate.

REGISTER HERE 

It will include a live demonstration of the robotic exoskeleton developed by Rex, which is helping the wheelchair-bound walk again. CLICK HERE FOR THE VIDEO.

The company, the inventors behind it, and this ground-breaking technology have received national media coverage (click here). Thursday provides the opportunity to meet the Rex team and quiz them.

If standing in line at the amusement park in the sweltering summer heat isn’t your thing, then you’ll want to hear more from Accesso.

Commercially it is gaining huge traction for its virtual queuing and ticketing as record results for the past year revealed.

Revenues rose by 22% to US$75.1mln with the improvement stronger on a pro-forma basis.

Tom Burnet, Accesso’s chief executive, will tell us what investors can expect in 2015. 

Akers Biosciences, headed by founder Ray Akers, is at a crucial juncture as moves out of the development phase and brings the first of its new diagnostic kits to the market.

Last month it revealed sales of its test for people with an allergy to blood thinner Heparin more than doubled in 2014.

It was the driver behind a 24% rise in sales overall at the diagnostic test group, which also saw a first US$1mln order from China.

Total sales rose by 24% to US$4.43mln, with a US$864,000 order also received for its rapid cholesterol test for Australia, Singapore and the Middle East.

Last, but by no means least, is Alliance Pharma, a great backstop investment for any small-cap portfolio.

This is the very essence of slow burner, although you wouldn’t know that from the 20% rise in the share price in the past month.

The company owns and acquires mature pharmaceutical products, with its expertise, is able to eke out greater returns from these prescription medicines than a larger organisation might.

Founded in 1998, it now has cabinet with around 60 different medicines in it. For the income investor there is even a dividend, which was jacked up 10% at the last results.

I’m sure you’ll agree we’ve got a great line up. Please join us at the Chesterfield Hotel, 35 Charles Street, Mayfair, from 6pm (REGISTER HERE). Get there early to bag a seat.

Quick facts: Akers Biosciences, Inc.

Price: 14.59 USD

NASDAQ:AKR
Market: NASDAQ
Market Cap: $1.27 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Great Bear Resources sees more impressive results from their...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver with the latest results from their large drill program on the Dix Project in Red Lake, Ontario. Taylor telling Proactive they have expanded the shallow high-grade gold at the LP fault...

21 hours, 32 minutes ago

3 min read